Literature DB >> 8481596

Visions for the future in osteoporosis research.

G R Mundy1.   

Abstract

An ideal therapeutic agent for osteoporosis-one that both inhibits osteoclastic bone resorption and stimulates new bone formation-is not currently available. Currently available resorption inhibitors (estrogen, bisphosphonates, and calcitonin) prevent further bone loss and stabilize bone mass. However, they have a negligible to very modest effect on bone formation over prolonged periods, and do not cause prolonged increases in bone mass. A universally acceptable bone formation stimulator is not currently available. Future research is likely to focus on the use of peptide growth factors to stimulate appositional bone growth, or on the use of low molecular weight compounds that may selectively stimulate bone cells to produce these factors in the local bone remodeling microenvironment.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8481596     DOI: 10.1007/bf01623224

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  28 in total

1.  In vivo effects of human recombinant transforming growth factor beta on bone turnover in normal mice.

Authors:  C Marcelli; A J Yates; G R Mundy
Journal:  J Bone Miner Res       Date:  1990-10       Impact factor: 6.741

2.  Characterization of the latent transforming growth factor beta complex in bone.

Authors:  J Pfeilschifter; L Bonewald; G R Mundy
Journal:  J Bone Miner Res       Date:  1990-01       Impact factor: 6.741

3.  Stimulation of bone formation in vivo by transforming growth factor-beta: remodeling of woven bone and lack of inhibition by indomethacin.

Authors:  E J Mackie; U Trechsel
Journal:  Bone       Date:  1990       Impact factor: 4.398

4.  Vanadate stimulates bone cell proliferation and bone collagen synthesis in vitro.

Authors:  K H Lau; H Tanimoto; D J Baylink
Journal:  Endocrinology       Date:  1988-12       Impact factor: 4.736

5.  A proposed mechanism of the mitogenic action of fluoride on bone cells: inhibition of the activity of an osteoblastic acid phosphatase.

Authors:  K H Lau; J R Farley; T K Freeman; D J Baylink
Journal:  Metabolism       Date:  1989-09       Impact factor: 8.694

6.  17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens.

Authors:  G Girasole; R L Jilka; G Passeri; S Boswell; G Boder; D C Williams; S C Manolagas
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

7.  In vivo stimulation of bone formation by transforming growth factor-beta.

Authors:  M Noda; J J Camilliere
Journal:  Endocrinology       Date:  1989-06       Impact factor: 4.736

8.  Mean wall thickness and formation periods of trabecular bone packets in idiopathic osteoporosis.

Authors:  A J Darby; P J Meunier
Journal:  Calcif Tissue Int       Date:  1981       Impact factor: 4.333

9.  Novel regulators of bone formation: molecular clones and activities.

Authors:  J M Wozney; V Rosen; A J Celeste; L M Mitsock; M J Whitters; R W Kriz; R M Hewick; E A Wang
Journal:  Science       Date:  1988-12-16       Impact factor: 47.728

10.  Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial.

Authors:  J Reeve; P J Meunier; J A Parsons; M Bernat; O L Bijvoet; P Courpron; C Edouard; L Klenerman; R M Neer; J C Renier; D Slovik; F J Vismans; J T Potts
Journal:  Br Med J       Date:  1980-06-07
View more
  1 in total

1.  Prevention of ovariectomy osteopenia in rats after vaginal administration of Hyaff 11 microspheres containing salmon calcitonin.

Authors:  E Bonucci; P Ballanti; P A Ramires; J L Richardson; L M Benedetti
Journal:  Calcif Tissue Int       Date:  1995-04       Impact factor: 4.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.